Recursion Pharmaceuticals annual debt-to-equity ratio
2021
2022
2023
2024
2025
Recursion Pharmaceuticals Debt-to-Equity Ratio Growth & History (RXRX)
Recursion Pharmaceuticals's debt-to-equity ratio was 0.06 for fiscal 2025.
View full Recursion Pharmaceuticals company overviewRecursion Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.06 | −0.04 | −37.02% |
| 2024 | 2024-12-31 | 0.10 | −0.01 | −11.49% |
| 2023 | 2023-12-31 | 0.11 | 0.01 | +5.37% |
| 2022 | 2022-12-31 | 0.10 | 0.10 | +7686.43% |
| 2021 | 2021-12-31 | 0.00 | — | — |
Recursion Pharmaceuticals quarterly debt-to-equity ratio
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.06 | −0.02 | −27.57% |
| Q1 2026 | 2026-03-31 | 0.06 | −0.03 | −31.79% |
| Q4 2025 | 2025-12-31 | 0.06 | −0.04 | −37.02% |
| Q3 2025 | 2025-09-30 | 0.07 | −0.09 | −55.34% |
| Q2 2025 | 2025-06-30 | 0.09 | −0.05 | −38.31% |
| Q1 2025 | 2025-03-31 | 0.09 | −0.03 | −27.34% |
| Q4 2024 | 2024-12-31 | 0.10 | −0.01 | −11.49% |
| Q3 2024 | 2024-09-30 | 0.16 | 0.04 | +38.56% |
| Q2 2024 | 2024-06-30 | 0.14 | 0.03 | +28.47% |
| Q1 2024 | 2024-03-31 | 0.12 | 0.01 | +4.38% |
| Q4 2023 | 2023-12-31 | 0.11 | 0.01 | +5.37% |
| Q3 2023 | 2023-09-30 | 0.11 | −0.02 | −14.63% |
| Q2 2023 | 2023-06-30 | 0.11 | −0.01 | −10.10% |
| Q1 2023 | 2023-03-31 | 0.12 | 0.01 | +14.31% |
| Q4 2022 | 2022-12-31 | 0.10 | 0.10 | +7686.43% |
| Q3 2022 | 2022-09-30 | 0.13 | 0.13 | +10593.04% |
| Q2 2022 | 2022-06-30 | 0.12 | 0.10 | +514.91% |
| Q1 2022 | 2022-03-31 | 0.10 | — | — |
| Q4 2021 | 2021-12-31 | 0.00 | — | — |
| Q3 2021 | 2021-09-30 | 0.00 | — | — |
| Q2 2021 | 2021-06-30 | 0.02 | — | — |
Recursion Pharmaceuticals debt-to-equity ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Recursion Pharmaceuticals's debt-to-equity ratio increased from 0.00 to 0.06, a change of 0.06. The latest reported quarter, Q2 2026, shows 0.06.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Recursion Pharmaceuticals source filings ↗